Evolution of human papillomavirus infection and associated lesions in men who have sex with HIV-positive men with increased risk of development of anal cancer. Study of viral markers associated with clinical progression (Q3161199): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): General objectives: Estimate the serial prevalence, incidence and clearance of high-risk HPV infections (HPV-AR) and anal squamous intraepithelial lesions (ALSIL), and their determinants in men who have sex with men (SHH), HIV positive from the CoRIS-VPH cohort (2007-2016); Evaluate the diagnostic value and prognosis of clinical progression of expression of oncoproteins E6/E7 of HPV-AR 16, 18, 31, 33 and 45. Design: Multicenter cohort study. Sco...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Evolution of human papillomavirus infection and associated lesions in men who have sex with HIV-positive men with increased risk of development of anal cancer. Study of viral markers associated with clinical progression | |||
Revision as of 16:44, 12 October 2021
Project Q3161199 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Evolution of human papillomavirus infection and associated lesions in men who have sex with HIV-positive men with increased risk of development of anal cancer. Study of viral markers associated with clinical progression |
Project Q3161199 in Spain |
Statements
1,450.0 Euro
0 references
2,900.0 Euro
0 references
50.0 percent
0 references
1 January 2014
0 references
30 September 2017
0 references
FUNDACION PARA EL FOMENTO DE LA INV. SANITARIA Y BIOMEDICA DE LA COMUNIDAD VALENCIANA (FISABIO)
0 references
38°15'55.19"N, 0°41'55.82"W
0 references
03065
0 references
Objetivos generales: Estimar la prevalencia seriada, incidencia y aclaramiento de las infecciones por el VPH de alto riesgo (VPH-AR) y las lesiones intraepiteliales escamosas anales (SIL anal), y sus determinantes en hombres que tienen sexo con hombres (HSH), VIH positivos de la cohorte CoRIS-VPH (2007-2016); Evaluar el valor diagnóstico y pronóstico de progresión clínica de la expresión de las oncoproteínas E6/E7 de los VPH-AR 16, 18, 31, 33 y 45. Diseño: Estudio de cohortes multicéntrico. Ámbito de estudio: Cohorte de 1.500 hombres (CoRIS-VPH) establecida en enero de 2007 y enmarcada en la Cohorte de la Red de Investigación de SIDA (CoRIS). Metodología: Se continuará con el seguimiento anual de los pacientes de la cohorte, recogiendo datos epidemiológicos, clínicos y de conducta sexual, así como muestras anales para diagnóstico citológico (en medio líquido) y estudio virológico (identificación de tipos de VPH-AR), de acuerdo a los criterios establecidos en CoRIS-VPH. En las muestras en las que se detecten los tipos más frecuentemente detectados en los casos de cáncer (VPH 16, 18, 31, 33 y 45), se determinará la expresión de las oncoproteínas E6/E7. Análisis estadístico: Se realizará el análisis descriptivo de las variables del estudio comparando diferencias mediante las pruebas estadísticas habituales. Se modelizará la incidencia y aclaramiento de VPH-AR y SIL anal mediante regresión en un modelo multi-estado teniendo en cuenta la censura por intervalos, calculando Riesgos Relativos (RR) y sus intervalos de confianza (IC) 95% ajustando por las variables de confusión y valorando las posibles interacciones. (Spanish)
0 references
General objectives: Estimate the serial prevalence, incidence and clearance of high-risk HPV infections (HPV-AR) and anal squamous intraepithelial lesions (ALSIL), and their determinants in men who have sex with men (SHH), HIV positive from the CoRIS-VPH cohort (2007-2016); Evaluate the diagnostic value and prognosis of clinical progression of expression of oncoproteins E6/E7 of HPV-AR 16, 18, 31, 33 and 45. Design: Multicenter cohort study. Scope of study: Cohort of 1,500 men (CoRIS-VPH) established in January 2007 and framed in the Cohort of the AIDS Research Network (CoRIS). Methodology: Annual follow-up of patients in the cohort will be continued, collecting epidemiological, clinical and sexual conduct data, as well as anal samples for cytological diagnosis (liquid medium) and virological study (identification of HPV-AR types), according to the criteria established in CoRIS-PHV. The expression of E6/E7 oncoproteins shall be determined in samples that detect the most frequently detected types in cancer cases (PHV 16, 18, 31, 33 and 45). Statistical analysis: The descriptive analysis of the variables of the study will be performed by comparing differences using the usual statistical tests. The incidence and clearance of HPV-AR and anal SIL shall be modelled by regression in a multi-state model, taking into account interval censorship, calculating Relative Risks (RR) and their 95 % confidence intervals (CI) adjusting for confusion variables and assessing possible interactions. (English)
12 October 2021
0 references
Elche/Elx
0 references
Identifiers
PI13_02155
0 references